Larry Borish is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Lee St
Charlottesville, VA 229080001
Telephone
434-924-0000Registry record last updated 8 Jul 2007.
Clinical trials
- Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
Sponsor: University of Virginia
- Viral Infection in Asthma (VIA) Study
Sponsor: University of Virginia
- Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency
Sponsor: University of Virginia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20256 payments$10,307openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
42.2%Histamine-1 Receptor Antagonist11.9%Azelastine Hcl100%Part D<11 patientsLeukotriene Receptor Antagonist9.2%Montelukast Sodium100%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
29.2%Corticosteroid17.3%Prednisone100%Part D≥19 patientsProton pump inhibitor11.9%Omeprazole100%Part D<11 patientsDermatology
21.1%Interleukin-4 Receptor alpha Antagonist21.1%Dupixent Pen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
12 NIH research awards on record, funded 1999–2026 per NIH RePORTER. The latest:
- Exploring innate immune responses to rhinovirus in allergic asthma
University of Virginia
FY2026$80,750R03AI185854 - Exploring innate immune responses to rhinovirus in allergic asthma
University of Virginia
FY2025$80,750R03AI185854 - Protracted clinical and inflammatory response to rhinovirus challenge in human asthmatics
University of Virginia
FY2022$323,000R56AI158519
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”